[Skip to Navigation]
September 9, 2002

The Potential Role of Fondaparinux as Venous Thromboembolism Prophylaxis After Total Hip or Knee Replacement or Hip Fracture Surgery

Arch Intern Med. 2002;162(16):1806-1808. doi:10.1001/archinte.162.16.1806

VENOUS THROMBOEMBOLISM (VTE) is a common disease, with an average annual incidence of over 1 per 1000.1 Venous thromboembolism also is a potentially lethal disease, mostly owing to pulmonary embolism (PE). Almost one quarter of all PE cases present as essentially sudden death, with a 1-week survival of only 71%.2 Patients with deep vein thrombosis (DVT) often experience serious and costly long-term complications. Almost 30% of patients develop serious venous stasis syndrome within 10 years3,4 at an estimated cost of over $4000 per episode in 1997 dollars.5 To improve survival and prevent complications, the incidence of VTE must be reduced.

Add or change institution